<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2794-1140</journal-id>
<journal-title><![CDATA[Pharmaceutical Care España]]></journal-title>
<abbrev-journal-title><![CDATA[Pharm Care Esp.]]></abbrev-journal-title>
<issn>2794-1140</issn>
<publisher>
<publisher-name><![CDATA[Fundación Pharmaceutical Care España]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2794-11402024000101402</article-id>
<article-id pub-id-type="doi">10.60103/phc.v26.e846</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos del minoxidilo en formulación oral en pacientes barosensibles]]></article-title>
<article-title xml:lang="en"><![CDATA[Effects of minoxidil in oral formulation on barosensitive patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopez-Carmona]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Toro-Ruiz]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zarzuelo]]></surname>
<given-names><![CDATA[Maria Jose]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Granada Grupo de Investigación de Atención Farmacéutica ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Granada Facultad de Farmacia Departamento de Farmacia y Tecnología Farmacéutica]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>26</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2794-11402024000101402&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2794-11402024000101402&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2794-11402024000101402&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La prevalencia de la alopecia androgénica ha hecho que aumenten las consultas dermatológicas y las opciones de tratamiento. Las fórmulas orales que combinan minoxidilo e inhibidores de la 5-alfa-reductasa, como dutasterida, están ganando popularidad. Un joven de 22 años con alopecia androgénica, recibió una receta de este tipo en 2022. Tras recoger regularmente su medicación, en el verano de 2023 se quejó de mareos, taquicardia y palpitaciones. Las investigaciones revelaron una presión arterial baja y una frecuencia cardiaca elevada. Sospechando reacciones adversas al medicamento, los farmacéuticos iniciaron un seguimiento. Aunque se confirmó que la formulación y el lote eran seguros, los posibles efectos secundarios del minoxidilo suscitaron preocupación. Su dermatólogo suspendió el minoxidilo durante las vacaciones costeras, con lo que se resolvieron los síntomas. A la vuelta, al reanudar el tratamiento con minoxidilo/dutasterida, los síntomas remitieron y la tensión arterial monitorizada volvió a la media. Este caso pone de relieve la importancia de la farmacovigilancia y la terapia individualizada en el manejo de las reacciones adversas a los tratamientos de la alopecia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The prevalence of androgenic alopecia has led to increased dermatological consultations and treatment options. Oral formulations combining minoxidil and 5-alpha-reductase inhibitors like dutasteride are gaining popularity. A 22-year-old man with androgenic alopecia, received such a prescription in 2022. After regularly picking up his medication, he complained of dizziness, tachycardia, and palpitations in summer 2023. Investigations revealed low blood pressure and elevated heart rate. Suspecting adverse drug reactions, pharmacists initiated a follow-up. Although the formulation and batch were confirmed to be safe, the potential side effects of minoxidil raised concerns. His dermatologist discontinued minoxidil during a coastal holidays, resolving symptoms. Upon return, when he resumed minoxidil/dutasteride treatment, his symptoms subsided and his monitored blood pressure returned to average. This case highlights the importance of pharmacovigilance and individualized therapy in the management of adverse reactions to alopecia treatments.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Minoxidilo]]></kwd>
<kwd lng="es"><![CDATA[Farmacéutico]]></kwd>
<kwd lng="es"><![CDATA[Caso Clínico]]></kwd>
<kwd lng="es"><![CDATA[Farmacovigilancia]]></kwd>
<kwd lng="en"><![CDATA[Minoxidil, Pharmacist]]></kwd>
<kwd lng="en"><![CDATA[Clinical Case]]></kwd>
<kwd lng="en"><![CDATA[Pharmacovigilance]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
<name>
<surname><![CDATA[Hermann]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Morrill]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Hobbs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2004</year>
<volume>89</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2179-84</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[Ficha técnica de minoxidilo 10mg]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[Ficha técnica de minoxidilo 50 mg/ml solución cutánea]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubrey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[VanGriethuysen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A hairy fall: syncope resulting from topical application of minoxidil]]></article-title>
<source><![CDATA[BMJ Case Rep]]></source>
<year>2015</year>
<volume>2015</volume>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vañó-Galván]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Crehuet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Garnacho]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Zubiaur]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hermosa-Gelbard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Arrones]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Saceda-Corralo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano-Falcón]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones sobre el manejo clínico de la alopecia androgénica: un documento de consenso del Grupo Español de Tricología de la AEDV]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2024</year>
<volume>115</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>347-55</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Talukder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparación de minoxidil oral, finasterida y dutasterida para el tratamiento de la alopecia androgenética]]></article-title>
<source><![CDATA[J Dermatolog Treat]]></source>
<year>2022</year>
<volume>33</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2946-62</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halonen]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Zanobetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sparrow]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vokonas]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between outdoor temperature and blood pressure]]></article-title>
<source><![CDATA[Occup Environ Med]]></source>
<year>2011</year>
<volume>68</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>296-301</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fonseca-Reyes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca-Cortés]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Parra-Carrillo]]></surname>
<given-names><![CDATA[JZ]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Velarde]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Temperatura atmosférica y su efecto sobre presión arterial en pacientes con hipertensión arterial]]></article-title>
<source><![CDATA[Sal Jal]]></source>
<year>2021</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>78-84</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malamud-Kessler]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chiquete]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Senties-Madrid]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Campos-Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fisiopatología del síncope neuralmente mediado]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2016</year>
<volume>31</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>620-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<source><![CDATA[Ficha técnica de minoxidilo para fórmula magistral (acofarma)]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
